

EXTRACORPOREAL NEPHROLOGY GROUP [ECNG]

HTK SOLUTION

DR VILESH VALSALAN


CONSULTANT NEPHROLOGIST AND TRANSPLANT PHYSICIAN

ACADEMIC CORDINATOR - ECNG

INTRODUCTION

- HTK solution is a specialised intracellular crystalloid solution used primarily for organ preservation.
- The acronym HTK stands for its three critical active ingredients: **Histidine, Tryptophan, and Ketoglutarate.**
- **Histidine:** Actively works as a powerful **amino acid buffer.** It maintains normal physiological pH and limits tissue damage caused by lactic acid buildup,
- **Tryptophan:** Functions as a **membrane-protective stabilizer,** preventing ion leakage across cellular barriers during transport.
- **Ketoglutarate:** Serves as a vital **energy substrate** that allows the tissue to restart internal ATP production quickly once blood flow is restored.
- **Mannitol:** Included as an osmotic agent to **decrease risk of cell swelling and hunt down oxygen-free radicals.**

Steps in kidney transplantation




1812 - Le Gallois

"if the place of the heart could be supplied by injection—and if, for the regular continuance of this injection, there could be furnished a quantity of arterial blood, whether natural or artificially formed, supposing such a formation possible—then life might be indefinitely maintained in any portion"

1849 - Loebell

first perfusion experiments on isolated pig kidneys



1885 - Von Frey and Gruber

First closed artificial circulation system similar to today's organ perfusion systems

1953 - Lapchinsky

First animal models of hypothermic preservation of kidneys with successful transplantation



1935 - Lindberg and Carrel
Pressurized Normothermic Oxygenated system organs viable 3-21 days



1954 - Murray

First successful kidney transplant between twins at Brigham and Women's Hospital

1968 - Belzer

Successful human kidney transplant after 17 hours preservation in static, hypothermic plasma perfusion

1969 - Collins

30 hours static cold storage with transplant in Collins solution

1986 - Wahlberg

UW solution

1975 - Bretschneider

HTK solution first described As a cardioplegia agent



2011 - Hosgood

First normothermic machine perfusion renal transplant

1870 1880 1890 1900 1910 1920 1930 1940 1950 1960 1970 1980 1990 2000 2010 2020

Normothermia

Hypothermia

Hypothermic Machine Perfusion

Ischemia Reperfusion Injury (IRI)

ISCHEMIC INJURY

- **Metabolic Switch:** Deprived of oxygen, cells switch from aerobic to **anaerobic metabolism**, leading to rapid depletion of adenosine triphosphate (ATP).
- **Intracellular Acidosis:** Anaerobic glycolysis causes **lactate accumulation**, lowering intracellular pH.
- **Ionic Imbalance:** Failure of ATP-dependent pumps (Na⁺/K⁺ ATPase, Ca²⁺ ATPase) leads to an influx of sodium and water (**cellular oedema**) and a toxic build up of **cytosolic calcium**.
- **Priming for Damage:** ATP breakdown products like **hypoxanthine** accumulate, serving as precursors for reactive oxygen species (ROS) during the next phase.

REPERFUSION (PARADOXICAL INJURY)

Reperfusion restores oxygen and normalises pH, but this triggers a massive destructive cascade.

- **ROS Burst:** The sudden reintroduction of oxygen leads to a "burst" of **Reactive Oxygen Species (ROS)** production, causing extensive **lipid peroxidation** of cell membranes and DNA damage.
- **Mitochondrial Dysfunction:** ROS and calcium overload trigger the opening of **mitochondrial permeability transition pores (mPTP)**, leading to the release of pro-apoptotic factors like cytochrome C and succinate.
- **No-Reflow Phenomenon:** Despite clearing the physical obstruction, microvascular blood flow remains compromised due to endothelial cell swelling, microthrombi (clots), and intense vasoconstriction.

The Ideal Preservation Solution

- ◆ Prevents cell swelling and tissue edema
 - Osmotic agents: hydroxy ethyl starch, lactobionate, mannitol, tryptophan
- ◆ Maintains intracellular pH
 - Histidine
- ◆ Provides substrates for generation of ATP
 - Adenosine, α -ketoglutarate, L-arginine
- ◆ Prevent oxygen free-radical injury
 - Glutathione, allopurinol, N-Acetylcysteine

Composition

Component	University of Wisconsin	Histidine Tryptophan α Ketoglutarate (HTK)
K+	125	10
Na+	25	15
Cl-	15	32
Ca ²⁺	-	0.015
Mg ²⁺	5	4
Colloid/Impermeant	Pentaraction Lactobionate Raffinose	Mannitol
Buffer	Phosphate	Histidine
Antioxidant	Glutathione Alloppurinol	Tryptophan α Ketoglutarate
Aminoacids	-	Histidine Tryptophan
Other	Adenosine Sulfate	-

RL is NOT an ideal perfusion solution

- High Na & Cl levels ; during Cl ; **increases fluid entry** into cells ; membrane integrity / **cell swelling** , poor ischemic tolerance.
- Contains Ca ; causes **Ca influx -> mitochondrial damage** / activates apoptosis.
- Contains lactate as buffering agent ; **poor maintenance of pH** and biochemical stability.
- FDA – RL as resuscitation crystalloid.

Comparison of UW and HTK solution

Feature / Metric	University of Wisconsin (UW) Solution	Histidine-Tryptophan-Ketoglutarate (HTK) Solution
Solution Type	Intracellular-like (high K ⁺ , low Na ⁺)	Extracellular-like (low K ⁺ , high Na ⁺)
Viscosity	High (contains Hydroxyethyl starch colloid)	Low (no colloids, flows freely)
Primary Buffer	Phosphate	Histidine (excellent buffering capacity)
Potassium Level	High (≈ 125 mmol/L)	Low (≈ 9 mmol/L)
Flush Preparation	Requires mandatory rinsing/flushing before reperfusion to prevent hyperkalaemic cardiac arrest.	Can be reperfused with less risk of severe cardiac arrhythmias.
Required Volume	Low to moderate volume needed per organ.	High volume required to achieve deep cooling and complete clearing.
Ischemia Tolerance	Superior protection during prolonged cold ischemia (>8–15 hours).	Excellent for shorter times; slightly higher risk of tissue injury during long cold storage.
Primary Advantage	Gold standard for extended preservation and complex/marginal grafts.	Fast organ cooling, easier microvascular clearing, and lower cost .

HTK –N solution

- **HTK-N modifies the molecular baseline of traditional HTK to combat the specific cellular mechanisms of Ischemia-Reperfusion Injury.**
- **Dual Iron Chelators:** Includes **deferoxamine** (poorly membrane-permeable) and **LK 614** (highly membrane-permeable). Together, they bind "redox-active" iron released during cold storage, drastically reducing the generation of ROS.
- **Membrane-Stabilizing Amino Acids:** Supplemented with **glycine** and **alanine**. These inhibit the formation of hypoxia-induced plasma membrane pores, successfully preventing cell swelling and premature lysis.
- **Endothelial Function Boost:** Infused with **L-arginine** to act as a substrate for nitric oxide production, which minimizes microcirculatory vasospasms upon graft reperfusion.
- **Modified Buffering & Osmolyte Swap:** Standard histidine has been partially replaced with **N-acetyl-histidine** to lower cell toxicity.